# Lifecore Biomedical, Inc. \\de\\: Form 10-Q for the period ended Mar 31, 2026

- Company: [Lifecore Biomedical, Inc. \\de\\](/companies/lfcr.md) (CIK 1005286)
- Form: 10-Q
- Filed: 2026-05-06
- Accepted by EDGAR: May 6, 2026, 07:22 ET
- Period: 2026-03-31
- Accession: 0001005286-26-000020
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000020/lfcr-20260331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000020/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2026-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2026-01-01 to 2026-03-31 | $23.2m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months, 2026-01-01 to 2026-03-31 | $18.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2026-01-01 to 2026-03-31 | $4.5m | us-gaap:GrossProfit |
| Research and development | 3 months, 2026-01-01 to 2026-03-31 | $1.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2026-01-01 to 2026-03-31 | $7.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2026-01-01 to 2026-03-31 | −$4.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2026-01-01 to 2026-03-31 | $43.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2026-01-01 to 2026-03-31 | −$15.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2026-01-01 to 2026-03-31 | −$0.43 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2026-01-01 to 2026-03-31 | −$0.43 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2026-01-01 to 2026-03-31 | 37,477,386 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2026-01-01 to 2026-03-31 | $4.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2026-01-01 to 2026-03-31 | $1.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2026-03-31 | $20.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2026-03-31 | $77.6m | us-gaap:AssetsCurrent |
| Total assets | at 2026-03-31 | $225.5m | us-gaap:Assets |
| Current liabilities | at 2026-03-31 | $20.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2026-03-31 | $204.7m | us-gaap:Liabilities |
| Long-term debt | at 2026-03-31 | $148.7m | us-gaap:LongTermDebt |
| Current portion of debt | at 2026-03-31 | $962.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2026-03-31 | −$28.4m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1005286/000100528626000020/lfcr-20260331.htm

Filed May 6, 2026.
Source: SEC EDGAR, the filing index for accession 0001005286-26-000020. Last ingested by Listed: Nov 5, 2026, 12:15 ET. No prices; not investment advice.